Northern Trust Corp 89bio, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in 89bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 854,787 shares of ETNB stock, worth $9.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

854,787

Previous 794,712 7.56%

Holding current value

$9.35 Million

Previous $5.88 Million 11.5%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.03 - $10.05 $422,327 - $603,753	60,075 Added 7.56%	854,787 $6.56 Million
Q3 2024 Nov 13, 2024	BUY	$7.36 - $9.66 $521,441 - $684,391	70,848 Added 9.79%	794,712 $5.88 Million
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $68,224 - $101,729	9,333 Added 1.31%	723,864 $5.8 Million
Q1 2024 May 14, 2024	BUY	$8.13 - $13.77 $784,788 - $1.33 Million	96,530 Added 15.62%	714,531 $8.32 Million
Q4 2023 Feb 13, 2024	BUY	$6.66 - $16.03 $248,677 - $598,544	37,339 Added 6.43%	618,001 $6.9 Million
Q3 2023 Nov 13, 2023	BUY	$15.06 - $19.41 $316,711 - $408,192	21,030 Added 3.76%	580,662 $8.97 Million
Q2 2023 Aug 11, 2023	BUY	$14.15 - $22.03 $6.48 Million - $10.1 Million	458,040 Added 450.86%	559,632 $10.6 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $390,547 - $631,286	37,266 Added 57.93%	101,592 $1.55 Million
Q4 2022 Feb 13, 2023	SELL	$5.52 - $12.73 $24,017 - $55,388	-4,351 Reduced 6.34%	64,326 $818,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $102,683 - $238,007	34,001 Added 98.05%	68,677 $398,000
Q2 2022 Aug 12, 2022	SELL	$2.09 - $4.02 $133,532 - $256,841	-63,891 Reduced 64.82%	34,676 $112,000
Q1 2022 May 13, 2022	SELL	$3.45 - $14.99 $13,189 - $57,306	-3,823 Reduced 3.73%	98,567 $371,000
Q4 2021 Feb 08, 2022	SELL	$11.15 - $19.66 $9,834 - $17,340	-882 Reduced 0.85%	102,390 $1.34 Million
Q3 2021 Nov 15, 2021	SELL	$14.91 - $21.31 $270,497 - $386,606	-18,142 Reduced 14.94%	103,272 $2.02 Million
Q2 2021 Aug 13, 2021	BUY	$17.42 - $28.0 $4,685 - $7,532	269 Added 0.22%	121,414 $2.27 Million
Q1 2021 May 12, 2021	SELL	$20.22 - $26.73 $378,922 - $500,920	-18,740 Reduced 13.4%	121,145 $2.87 Million
Q4 2020 Feb 11, 2021	BUY	$23.16 - $28.08 $613,415 - $743,726	26,486 Added 23.36%	139,885 $3.41 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $782,092 - $1.25 Million	32,132 Added 39.54%	113,399 $2.91 Million
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $763,777 - $1.2 Million	38,323 Added 89.24%	81,267 $1.62 Million
Q1 2020 May 14, 2020	BUY	$16.4 - $41.77 $215,331 - $548,440	13,130 Added 44.04%	42,944 $1.08 Million
Q4 2019 Feb 14, 2020	BUY	$19.75 - $33.44 $588,826 - $996,980	29,814 New	29,814 $784,000

Others Institutions Holding ETNB

# of Institutions

173

Shares Held

125M

Call Options Held

78.7K

Put Options Held

979K

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $509M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp 89bio, Inc. Transaction History